8 completed. 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 8 |
Follow selatogrel: new trials by email Literature Review of selatogrel trials Research Report on selatogrel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Chinese Adults With Chronic Coronary Syndrome Selatogrel, Matching placebo - Chronic Coronary Syndrome | Phase 1 | Completed | Viatris Innovation GmbH | 20 | 2026-06-22 | 2026-10-27 |
| A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Japanese and Caucasian Healthy Participants Selatogrel, Matching placebo - Healthy Volunteers | Phase 1 | Completed | Viatris Innovation GmbH | 32 | 2025-10-07 | 2026-07-14 |
| A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects Selatogrel - Healthy Subjects | Phase 1 | Completed | Viatris Innovation GmbH | 24 | 2020-11-06 | 2025-07-03 |
| The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics Selatogrel - Healthy Subjects, Hepatic Impairment | Phase 1 | Completed | Viatris Innovation GmbH | 24 | 2020-07-22 | 2025-07-04 |
| A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects Saline, ACT-246475, Rifampicin - Healthy Subject | Phase 1 | Completed | Viatris Innovation GmbH | 14 | 2019-01-03 | 2025-07-03 |
| A Study to Evaluate ACT-246475 Fate in Healthy Male Subjects ACT-246475 - Healthy Subjects | Phase 1 | Completed | Viatris Innovation GmbH | 6 | 2018-07-27 | 2025-07-03 |
| A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects ACT-246475, Clopidogrel, Prasugrel - Healthy | Phase 1 | Completed | Viatris Innovation GmbH | 77 | 2018-01-24 | 2025-07-03 |
| Single-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 / ACT-246475 in Healthy Male Subjects 5 mg ACT-281959 prodrug formulation I (Group A), 20 mg ACT-281959 prodrug formulation I (Group B), ACT-281959 prodrug formulation I (Groups C to G doses to be defined) - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 49 | 2011-10-01 | 2018-07-10 |
Viatris Innovation GmbH (7) · Idorsia Pharmaceuticals Ltd. (1)
United States (3) · Germany (2) · China (1) · France (1) · Netherlands (1)
Daniela Baldoni, PharmD PhD (1)
PMID 32166864, PMID 33412611, PMID 34961905
2017 (1), 2018 (1)